Alembic Pharmaceuticals announced on Friday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of a drug used to prevent heart attacks and strokes.
The company has been granted final approval for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 90 mg, and tentative approval for the 60 mg strength. According to the statement, Alembic’s product is therapeutically equivalent to AstraZeneca’s Brilinta Tablets in both 60 mg and 90 mg doses.